VERAXA Biotech AG (NASDAQ: VRXA) has appointed antibody therapeutics specialist Dr. Christoph Erkel as its new Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC® technology platform toward clinical development. Dr. Erkel, previously Vice President of Research & Development, will lead scientific strategy across the company’s BiTAC® platforms and broader oncology pipeline, directing efforts to accelerate product candidates.
The leadership change comes as VERAXA progresses its diversified oncology pipeline, which includes conditionally active T-cell engagers, bispecific antibody-drug conjugates, and other engineered antibody therapeutics. The company recently received regulatory feedback from Germany’s Paul-Ehrlich-Institute, providing additional clarity for the development of its lead BiTAC®-TCE program. This milestone is critical as VERAXA prepares to enter the clinic with its next-generation immunotherapies designed to improve efficacy while reducing treatment-related toxicity.
Dr. Erkel’s appointment underscores VERAXA’s commitment to strengthening its scientific leadership during a pivotal phase. The company is building a pipeline of novel cancer therapies that leverage its BiTAC® platform, which aims to engage T-cells more selectively against tumors. Investors are closely watching companies developing such next-generation immunotherapies, as they seek to address limitations of existing treatments.
For more information on VERAXA and its latest updates, visit the company’s newsroom at https://ibn.fm/VRXA.
